Prostate Cancer Screening: the Problem of Overdiagnosis and Lessons to Be Learned from Breast Cancer Screening
Overview
Affiliations
Screening for prostate cancer is a relatively new procedure, still under experimental evaluation within prospective randomised trials. The design of prospective studies has been mainly based on the experience of other cancer screenings, particularly breast cancer, for which data of several controlled studies are available. Unfortunately, breast cancer is very different from prostate cancer, particularly for aspects such as early diagnosis and, thus the screening process, originally modelled on the basis of the lesson taught by breast cancer screening, needs continuous re-evaluation and adjustment, based on data which are now being produced from ongoing screening experiences. In this paper, we will consider the most controversial aspects of prostate cancer screening and compare prostate screening with breast cancer screening in order to promote a better understanding of the current problems and lessons to be learned.
A meta-analysis for the diagnostic accuracy of SelectMDx in prostate cancer.
Wu H, Wu Y, He P, Liang J, Xu X, Ji C PLoS One. 2024; 19(2):e0285745.
PMID: 38329970 PMC: 10852267. DOI: 10.1371/journal.pone.0285745.
Feng T, Wei D, Li Q, Yang X, Han Y, Luo Y Front Genet. 2021; 12:584164.
PMID: 33927744 PMC: 8078837. DOI: 10.3389/fgene.2021.584164.
Song Z, Chao F, Zhuo Z, Ma Z, Li W, Chen G Aging (Albany NY). 2019; 11(13):4736-4756.
PMID: 31306099 PMC: 6660050. DOI: 10.18632/aging.102087.
Cava C, Bertoli G, Colaprico A, Bontempi G, Mauri G, Castiglioni I Int J Mol Sci. 2018; 19(3).
PMID: 29562723 PMC: 5877771. DOI: 10.3390/ijms19030910.
In Vivo Evaluation of a Bombesin Analogue Labeled with Ga-68 and Co-55/57.
Dam J, Olsen B, Baun C, Hoilund-Carlsen P, Thisgaard H Mol Imaging Biol. 2015; 18(3):368-76.
PMID: 26561028 DOI: 10.1007/s11307-015-0911-z.